4-Hydroxy-TEMPO

NurExone Biologic Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery

Retrieved on: 
Thursday, July 20, 2023
Real-time, EV, 3D, FSE, LPS, Patent Cooperation Treaty, Attention, Inflammation, Cell, PCT, Microsoft Exchange Server, NRX, EVS, TEL, Ren, Seminal vesicles, 3D bioprinting, Patent, Immune system, B cell, Fig, RAW, HPRT, Vaccine, 4-Hydroxy-TEMPO, Technion – Israel Institute of Technology

TORONTO and TEL AVIV, Israel, July 20, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in extracellular vesicles (EVs) functionality.

Key Points: 
  • TORONTO and TEL AVIV, Israel, July 20, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in extracellular vesicles (EVs) functionality.
  • Leveraging its proprietary and patented 3D-Flow production, the Company has achieved significantly enhanced EV functionality.
  • Through state-of-the-art production methodologies, NurExone aims to unlock the full potential of EVs as powerful therapeutic tools.
  • This is critical to ensure targeted delivery of therapeutic cargo to specific cell types, maximizing the potential of EVs as drug delivery vehicles.

Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 14, 2022
COVID-19, SAN, Allergy, Adrenaline, Partnership, Naloxone, Patient, ADMP, Anaphylaxis, US, Emergency, Opioid overdose, Patent, Annual report, Sale, Research, Catalent, Form 10-K, FDA, Pharmaceutical industry, Retail, Video game, Eddie Fenech Adami, 4-Hydroxy-TEMPO

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today reported financial results for the third quarter of 2022 and provided an update on recent corporate developments.

Key Points: 
  • SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today reported financial results for the third quarter of 2022 and provided an update on recent corporate developments.
  • Unit sales increased 90% in the third quarter compared to the second quarter of 2022.
  • Total net revenue for the third quarter of 2022 was approximately $1.5 million compared to approximately $760,000 in the third quarter of 2021, an increase of 98%.
  • ET, during which Company executives will review financial information for the third quarter of 2022 and provide a corporate update.

Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update

Retrieved on: 
Monday, November 7, 2022
SAN, GLOBE, Forward-looking statement, Opioid overdose, ADMP, Adrenaline, COVID-19, NASDAQ, News, Naloxone, 4-Hydroxy-TEMPO, Goal, Emergency, Allergy, Anaphylaxis, Patient, CEO, FDA, Pharmaceutical industry

SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, November 14, 2022 at 2:00 p.m. PT to discuss its financial and operating results for the third quarter 2022 as well as provide a corporate update.

Key Points: 
  • SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, November 14, 2022 at 2:00 p.m. PT to discuss its financial and operating results for the third quarter 2022 as well as provide a corporate update.
  • The companys third quarter 2022 financial results news release is expected to be available after 1 p.m. PT on November 14, 2022, and on its website .
  • David J. Marguglio, President and CEO of Adamis, will host the call along with other members of the management team.
  • For additional information aboutAdamis Pharmaceuticals, please visit our website and follow us on Twitter and LinkedIn .

Adamis Announces Review of Strategic Alternatives

Retrieved on: 
Monday, October 3, 2022
GLOBE, NASDAQ, SEC, LinkedIn, Form 10-K, Private Securities Litigation Reform Act, Anaphylaxis, Twitter, FDA, COVID-19, Naloxone, Goal, Emergency, Allergy, Partnership, Opioid overdose, U.S. Securities and Exchange Commission, SAN, Sale, Eddie Fenech Adami, Security (finance), Patient, Acquisition, Adrenaline, Disclosure, Annual report, ADMP, Company, Pharmaceutical industry, Risk management, 4-Hydroxy-TEMPO

As part of this process, the Company has engaged the investment bank Raymond James & Associates, Inc. to act as strategic advisor to assist the Company in evaluating certain alternatives.

Key Points: 
  • As part of this process, the Company has engaged the investment bank Raymond James & Associates, Inc. to act as strategic advisor to assist the Company in evaluating certain alternatives.
  • There can be no assurance that this strategic review process will result in the Company pursuing any transaction or that any transaction, if pursued, will be completed.
  • The Company has not established a schedule for completion of this strategic review process, nor has it made any definitive decisions at this time related to strategic alternative transactions.
  • If the Company is unable to complete a transaction, it may be required to seek bankruptcy protection or other alternatives for restructuring and resolving its liabilities.

Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

Retrieved on: 
Wednesday, September 21, 2022
Hospital, ADMP, Safety, Allergy, COVID-19, Twitter, FDA, MD, DSMB, Data monitoring committee, Opioid overdose, LinkedIn, Company, Obesity, Form 10-K, Private Securities Litigation Reform Act, Hypertension, COVID, Diabetes, Capsule, Patient, Cancer, Immunodeficiency, Goal, Emergency, Omicron, NASDAQ, Adrenaline, SAN, GLOBE, SEC, Naloxone, Annual report, Anaphylaxis, Pharmaceutical industry, Joam Mattheus Adami, 4-Hydroxy-TEMPO

The DSMB did note that no safety concerns were identified in the subjects that received Tempol.

Key Points: 
  • The DSMB did note that no safety concerns were identified in the subjects that received Tempol.
  • We are obviously disappointed that the study did not meet its endpoints, said Ron Moss, MD, Chief Medical Officer of Adamis.
  • I would like to thank our clinical research partners, the trial investigators and all the trial subjects for their participation.
  • Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial has been conducted.

Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

Retrieved on: 
Monday, September 12, 2022
Anaphylaxis, Inflammation, ADMP, EUA, Safety, Trial of the century, Allergy, COVID-19, Twitter, FDA, DSMB, Patient, Nitric oxide, Data monitoring committee, Opioid overdose, LinkedIn, Company, Obesity, Form 10-K, Intellectual property, Private Securities Litigation Reform Act, Hypertension, Metabolism, Diabetes, Capsule, Clinical trial, Agency, Cancer, Oxidative stress, Standard of care, Goal, Joam Mattheus Adami, Emergency, NASDAQ, Adrenaline, SAN, Reactive oxygen species, GLOBE, SEC, Mortality, HIV disease progression rates, Asthma, Naloxone, Annual report, Patent, Immunodeficiency, Pharmaceutical industry, 4-Hydroxy-TEMPO

SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248 subjects.

Key Points: 
  • Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248 subjects.
  • This interim meeting is significant as it will mark the first time the DSMB evaluates statistical measures of efficacy for Tempol.
  • Eligible subjects with positive COVID-19 infection within five days of study entry plus at least one co-morbidity were randomized one-to-one to receive either Tempol or placebo.
  • Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway.

Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders

Retrieved on: 
Friday, August 12, 2022
FDA, 4-Hydroxy-TEMPO, Annual Meetings of the International Monetary Fund and the World Bank Group, U.S. Securities and Exchange Commission, Board of directors, Emergency, GLOBE, Annual general meeting, Private Securities Litigation Reform Act, SEC, BDO, Board, Security (finance), Annual, Proposal 2, LLP, Allergy, Patient, Nasdaq, COVID-19, Twitter, Proxy, SAN, Form 10-K, Reverse stock split, NASDAQ, Opioid overdose, Goal, Anaphylaxis, ADMP, Adrenaline, LinkedIn, Naloxone, Annual report, Holding company, Eddie Fenech Adami, Director, Shareholder

SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (Annual Meeting) was convened, as scheduled.

Key Points: 
  • SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (Annual Meeting) was convened, as scheduled.
  • Based on feedback from Adamis stockholders related to the Reverse Stock Split Proposal, the independent members of the Adamis Board believe it is in the best interests of its stockholders to extend the opportunity for stockholders to vote on this important matter.
  • Therefore, the meeting was adjourned to allow additional time for stockholders to submit proxies with respect to the Reverse Stock Split Proposal.
  • The Annual Meeting will be reconvened on Thursday, September 8, 2022 at 10:00 a.m. Pacific Time (the sole matter of business before the reconvened Annual Meeting will be the Reverse Stock Split Proposal).

Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 10, 2022
FDA, CEO, Emergency, GLOBE, Failure, Private Securities Litigation Reform Act, SEC, Clinical trial, Sale, Patent, USWM, Government, Allergy, Patient, Syringe, Review, Data monitoring committee, COVID-19, Company, Twitter, SAN, DSMB, Martin PBM Mariner, Form 10-K, Safety, Awareness, NASDAQ, Research, Opioid overdose, Goal, Anaphylaxis, Employment, ADMP, Adrenaline, LinkedIn, Pharmacy, Naloxone, Degenerative disease, Annual report, USC, Pharmaceutical industry, 4-Hydroxy-TEMPO, Fagron, Eddie Fenech Adami

SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today reported financial results for the second quarter of 2022 and provided an update on recent corporate developments.

Key Points: 
  • SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today reported financial results for the second quarter of 2022 and provided an update on recent corporate developments.
  • I committed to the CEO role in May because I could see beyond Adamis current position to where it could go.
  • Many customers feel ZIMHIs combination of a higher dose with intramuscular delivery provides an advantage and significantly differentiates it from the leading competitors.
  • ET / 1:30 p.m. PT, during which Company executives will review financial information for the second quarter of 2022 and provide a corporate update.

Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update

Retrieved on: 
Monday, August 8, 2022
FDA, 4-Hydroxy-TEMPO, CEO, Emergency, GLOBE, Forward-looking statement, Allergy, Patient, COVID-19, Twitter, SAN, NASDAQ, Opioid overdose, Goal, Anaphylaxis, ADMP, Adrenaline, LinkedIn, Naloxone, Pharmaceutical industry

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Wednesday, August 10, 2022 at 1:30 p.m. Pacific Time to discuss its financial and operating results for the second quarter 2022 as well as provide a corporate update.

Key Points: 
  • SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Wednesday, August 10, 2022 at 1:30 p.m. Pacific Time to discuss its financial and operating results for the second quarter 2022 as well as provide a corporate update.
  • The companys press release concerning its second quarter 2022 financial results is expected to be available after 1 p.m. Pacific Time on August 10, 2022, and on its website .
  • David J. Marguglio, President and CEO of Adamis, will host the call along with other members of the management team.
  • For additional information about Adamis Pharmaceuticals, please visit our website and follow us on Twitter and LinkedIn .

Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Retrieved on: 
Friday, July 29, 2022
Oxidative stress, Allergy, Goal, Cytokine, COVID-19, Joam Mattheus Adami, GLOBE, Mortality, DSMB, Twitter, Trial of the century, Anaphylaxis, Naloxone, SEC, SAN, Intellectual property, Nitric oxide, Private Securities Litigation Reform Act, Patent, Safety, Metabolism, Reactive oxygen species, Asthma, NASDAQ, Opioid overdose, HIV disease progression rates, Clinical trial, Inflammation, Review, FDA, Company, Standard of care, Patient, LinkedIn, Adrenaline, Emergency, Annual report, Data monitoring committee, Form 10-K, ADMP, Pharmaceutical industry, 4-Hydroxy-TEMPO

SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Companys ongoing U.S.

Key Points: 
  • SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Companys ongoing U.S.
  • Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19.
  • If positive trends are observed in favor of the Tempol treatment group, the DSMB may recommend continuing the study along with the enrollment of additional subjects.
  • Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway.